User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -14.00 -1.56% 886.00 870.00 890.00 895.00 875.00 895.00 74,149 16:35:16
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 659

Maxcyte Share Discussion Threads

Showing 576 to 597 of 725 messages
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
DateSubjectAuthorDiscuss
26/2/2021
13:26
its good to have a fall, much needed consolidation going on - given all the large buys over the past 5 days (showing great institutional demand) will be interesting to see where it finds its level in the tricky market!
nimbo1
24/2/2021
14:29
Positive article with comments from James Brady Maxctye Vice President, Technical Applications and Customer Support hTTps://biobuzz.io/cell-and-gene-therapys-future-a-complex-mix-of-promise-and-pitfalls/
pob69
23/2/2021
07:47
Fingersxxxxd
assagai
23/2/2021
07:39
As these conference presentations are advertised as Corporate (rather than Clinical), I'm hoping they will coincide with the formal start of the Nasdaq application process.
someuwin
23/2/2021
07:33
https://www.google.com/url?rct=j&sa=t&url=https://www.fox8jobs.com/jobs/electromechanical-assembler-gaithersburg-maryland/234931826-2/&ct=ga&cd=CAEYACoUMTE4Mzg5NDY2NjkwNDUxMDUzODcyHDY0NjJhNDU2NjA4NmZhYTA6Y28udWs6ZW46R0I&usg=AFQjCNFumR_rVz67yC6sVyL7btDADfAy_Q
assagai
23/2/2021
07:05
MaxCyte, Inc. 22 February 2021 FOR IMMEDIATE RELEASE MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences GAITHERSBURG, MD, February 23, 2021 - MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows: Cowen 41st Annual Health Care Conference Who: Doug Doerfler, President & Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will present a corporate overview Dates: Virtual conference March 1 - 4, 2021 MaxCyte Presentation Details: March 1, 1:20 - 1:50 p.m. ET An archived version of the presentation will be made available following the conference in the Investors section of the Company website H.C. Wainwright & Co Global Life Sciences Conference Who: Doug Doerfler, President & Chief Executive Officer, will present a corporate overview Dates: Virtual conference March 9 - 10, 2021 MaxCyte Presentation Details: Available on demand to conference participants March 9 - 10, 2021
someuwin
22/2/2021
12:34
Interesting to note that Ark Genomic Revolution has bought into the CM Life Sciences SPAC which takes it a step closer to MXCT Crossover investor, and CM Life Sciences founding investor, Casdin Capital
rgmgo
22/2/2021
11:35
You are right Tom and I mentioned it at the time of the raise - D1 getting involved will have made other US institutions look - what is happening is UK institutions are trimming and US ones are buying imo. Very happy if it continues to consolidate up here because I was expecting more volatility given market conditions and the gains some people have already enjoyed.
nimbo1
22/2/2021
11:01
Huge trade volume continuing today - clearly the £10 level is the going rate for institutions to exchange millions of pounds of shares. Once this hits NASDAQ and gets discovered I agree it'll be multiples of the current level very quickly indeed, you simply wouldn't have this level of interest unless the technology AND commercial agreements offered an exceptional opportunity.
74tom
20/2/2021
18:47
Perfectly put Charlie. You will find the naysayers are as usual, those who missed the boat. I was one of those fortunate enough to get in before the start of the rise and any company that can make me 7figures in a year is welcome to their options. All I would say is that we are not even half way to where I think we will go over the next year or so.
assagai
20/2/2021
18:12
So it's OK for shareholders who do nothing to run a company to profit from other peoples work, but not for those who create wealth and work harder than I suspect you have an idea of to not? Weird world you must inhabit. They have stolen nothing. They have made anyone who joined this party cash - and significant cash to those who looked hard at MXCT as an investment in early days.
charliec51
19/2/2021
18:57
Looks like they’ve earned it to me
eaglebeagle
19/2/2021
18:16
I don't recall many complaints a year ago about options?
trickydicky1
19/2/2021
15:52
This chap Will Brooke just stole £415,135 pounds rightfully belonging to all shareholders, by issuing himself 40900 shares at whatever price and selling it on straight away at £10.15share. Clearly he must supplement his meagre earnings with this stolen freebee, which should be available to all shareholders at a similar proportion. The options of directors being able to issue themselves vast and unearned wealth should be abolished!
a1samu
18/2/2021
15:41
I dont think the options are excessive at all 2theduke - the 1040 strike price ensures that they aren't and completely aligns reward for execs with value creation for shareholders over the coming period. Just that options given to NEDs are unusual in a UK context...though then again they'll be Nasdq listed in a few months so I guess you could argue that they are indeed normal
adamb1978
18/2/2021
14:59
I have to agree with the NED options here. I think a very large case of making hay given the strength. It's the first action I'm not actually behind from them. I have no issue with prior options being cashed, nor incentive schemes. These however, and the size of them are certainly excessive in a "normal" market imo. Doesn't offset the wider strengths obviously but still.
2theduke
17/2/2021
21:35
Yes, very good that Nimbo. Being picky, granting options to NEDs is generally viewed poorly in the UK but more accepted in the US. However the decent strike price on the Exec options trumps that so overall its a good development for shareholders
adamb1978
17/2/2021
19:51
Chunky buys at the the close 16k 40k 25k
hatfullofsky
17/2/2021
09:09
hTTp://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-4 Comments on large scale manufacturing bodes well
nimbo1
16/2/2021
16:07
Just need to make sure the drawer is large enough to start with, put a lock on it, and then throw away the key (as you would do with Bitcoin...).
trickydicky1
16/2/2021
15:54
Not surprising really. I’ve said it before, but unless you’re following strict portfolio/ trading rules, eg no more than 20% in 1 stock or sell 1/2 if 100% up etc, I can’t see any reason to sell. We’ve seen a couple of valuations in the last 2 weeks both of which admit they are being conservative. Trinity Delta at 1217p in which they say “Our valuation approach leaves ample room for upside as MaxCyte continues to execute on its strategy” and “Our current valuation cannot adequately capture the scale of the future opportunity for MaxCyte,” And then Moats like Kodak, who felt Trinity too low, giving value of 1700p, which they admit is based on lowball assumptions. One to stick in the bottom drawer as they used to say.
acuere
16/2/2021
15:14
Looks like it really wants to move up.
someuwin
Chat Pages: 29  28  27  26  25  24  23  22  21  20  19  18  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210509 14:48:09